Publication: Pathologic changes in breast cancer after anti-estrogen therapy
1
Issued Date
2012-07-01
Resource Type
ISSN
15244741
1075122X
1075122X
Other identifier(s)
2-s2.0-84863722120
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Breast Journal. Vol.18, No.4 (2012), 362-366
Suggested Citation
Norasate Samarnthai, Richard Elledge, Thomas J. Prihoda, Jian Huang, Suleiman Massarweh, I. Tien Yeh Pathologic changes in breast cancer after anti-estrogen therapy. Breast Journal. Vol.18, No.4 (2012), 362-366. doi:10.1111/j.1524-4741.2012.01251.x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/14756
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pathologic changes in breast cancer after anti-estrogen therapy
Abstract
Breast cancer patients do not commonly receive anti-estrogens prior to surgical excision. We reviewed a cohort of patients who received preoperative anti-estrogen therapy after baseline biopsy and then had a repeat biopsy after several weeks on treatment. Patients with estrogen receptor positive tumors received anastrozole and fulvestrant in combination with gefitinib. Core needle biopsies were performed at day 1 and 21, and tumors were completely excised if operable at day 112. All patients were postmenopausal. Following treatment, tumors had degenerative changes including smudged nuclei, decreased nuclear size, intranuclear vacuoles, vacuolated cytoplasm, and increased cellular discohesion. In addition, increased tubule formation and intracytoplasmic lumina were seen in 6/9 cases (66.7%) and decreased mitotic rate was demonstrated in 7/9 cases (77.8%). These findings indicate increased differentiation of the tumor cells in response to anti-estrogen therapy and that may correlate with clinical response. © 2012 Wiley Periodicals, Inc.